Safety and activity of alflutinib in patients with advanced EGFR T790M mutation non-small cell lung cancer who progressed after EGFR-TKI therapy

被引：0
|
作者：
Shi, Y-K. [1 ]
Zhang, S. [2 ]
Hu, X. [1 ]
Feng, J. [3 ,14 ]
Ma, Z. [4 ]
Zhou, J. [5 ]
Yang, N. [6 ]
Wu, L. [7 ]
Liao, W. [8 ]
Han, X. [9 ]
Wang, Z. [10 ]
Zhang, X. [11 ]
Qin, S. [12 ]
Ying, K. [13 ]
Feng, J. [3 ,14 ]
Fang, J. [10 ]
Liu, L. [15 ]
Jiang, Y. [16 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Chest Hosp, Dept Oncol, Beijing, Peoples R China
[3] Jiangsu Canc Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China
[4] Henan Prov Canc Hosp, Dept Resp Med, Zhengzhou, Henan, Peoples R China
[5] Zhejiang Univ, Affiliated Hosp 1, Dept Resp Med, Coll Med, Hangzhou, Zhejiang, Peoples R China
[6] Hunan Canc Hosp, Dept Pulm Oncol, Changsha, Hunan, Peoples R China
[7] Hunan Canc Hosp, Dept Gastroenterol, Changsha, Hunan, Peoples R China
[8] Nanfang Med Univ, Nanfang Hosp, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
[9] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Beijing Key Lab Clin Study Anticanc Mol Targeted, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[10] Peking Univ, Dept Pulm Oncol, Canc Hosp, Beijing, Peoples R China
[11] Nantong Tumor Hosp, Dept Med Oncol, Nantong, Peoples R China
[12] Nanjing Univ Chinese Med, Med Oncol, PLA Canc Ctr, Bayi Hosp, Nanjing, Jiangsu, Peoples R China
[13] Zhejiang Univ, Sch Med, Dept Resp Med, Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China
[14] Nantong Univ, Dept Resp Med, Affiliated Hosp, Nantong, Peoples R China
[15] Huazhong Univ Sci & Technol, Union Hosp, Dept Thorac Oncol, Tongji Med Coll,Canc Ctr, Wuhan, Peoples R China
[16] Shanghai Allist Pharmaceut Inc, Clin Affairs & Regulatory Dept, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1531P
引用
收藏
页码：629 / 629
页数：1
相关论文
共 50 条
  • [21] Effect of EGFR-TKI targeted therapy in patients with advanced non-small cell lung cancer
    Yan, Meihao
    Chen, Shanshan
    Fan, Hongtao
    Hong, Yuancheng
    Huang, Wencheng
    Lin, Zhimin
    Lai, Zhangchao
    Hong, Liyue
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (11): : 7916 - 7923
  • [22] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [23] Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC
    Yang, Shuo
    Mao, Shiqi
    Li, Xuefei
    Zhao, Chao
    Liu, Qian
    Yu, Xiaofei
    Wang, Yan
    Liu, Yiwei
    Pan, Yingying
    Wang, Chunyan
    Gao, Guanghui
    Li, Wei
    Xiong, Anwen
    Chen, Bin
    Sun, Hui
    He, Yayi
    Wu, Fengying
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    LUNG CANCER, 2020, 139 : 133 - 139
  • [24] REBIOPSY OF NON-SMALL CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI: COMPARISON BETWEEN T790M MUTATION-POSITIVE AND -NEGATIVE POPULATIONS
    Hata, A.
    RESPIROLOGY, 2012, 17 : 82 - 82
  • [25] Rebiopsy of non-small cell lung cancer patients with acquired resistance to EGFR-TKI: Comparison between T790M mutation-positive and -negative populations
    Hata, Akito
    Katakami, Nobuyuki
    Yoshioka, Hiroshige
    Takeshita, Jumpei
    Tanaka, Kosuke
    Nanjo, Shigeki
    Kaji, Reiko
    Fujita, Shiro
    Imai, Yukihiro
    Monden, Kazuya
    Matsumoto, Takeshi
    Nagata, Kazuma
    Otsuka, Kyoko
    Tachikawa, Ryo
    Tomii, Keisuke
    Kunimasa, Kei
    Iwasaku, Masahiro
    Nishiyama, Akihiro
    Ishida, Tadashi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] A status of re-biopsy for non-small-cell lung cancer patients after first EGFR-TKI failure and incidence of T790M mutation
    Sakai, Tetsuya
    Udagawa, Hibiki
    Zenke, Yoshitaka
    Kirita, Keisuke
    Umemura, Shigeki
    Matsumoto, Shingo
    Yoh, Kiyotaka
    Niho, Seiji
    Ishii, Genichiro
    Goto, Koichi
    CANCER RESEARCH, 2019, 79 (13)
  • [27] T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer
    Watanabe, Satomi
    Yoshida, Takeshi
    Kawakami, Hisato
    Takegawa, Naoki
    Tanizaki, Junko
    Hayashi, Hidetoshi
    Takeda, Masayuki
    Yonesaka, Kimio
    Tsurutani, Junji
    Nakagawa, Kazuhiko
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (11) : 2563 - 2571
  • [28] Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure
    Yoshida, Tatsuya
    Kuroda, Hiroaki
    Oya, Yuko
    Shimizu, Junichi
    Horio, Yoshitsugu
    Sakao, Yukinori
    Hida, Toyoaki
    Yatabe, Yasushi
    LUNG CANCER, 2017, 109 : 89 - 91
  • [29] Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non-small-cell Lung Cancer with a T790M Mutation
    Togashi, Yosuke
    Hayashi, Hidetoshi
    Terashima, Masato
    de Velasco, Marco A.
    Sakai, Kazuko
    Fujita, Yoshihiko
    Tomida, Shuta
    Nakagawa, Kazuhiko
    Nishio, Kazuto
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (01) : 93 - 101
  • [30] Apatinib combined with EGFR-TKI in treating advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Xu, J.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2019, 30
12345